印度特发性炎症性肌病患者感染负担高:MyoCite数据集观察结果的验证
该研究在印度特发性炎症性肌病(IIM)队列中评估感染的患病率、特征和预测因素。观察队列68例中54.4%发生感染,结核最常见;验证队列70例中33.3%发生感染,社区获得性肺炎最常见。两队列中每日泼尼松剂量>6.25 mg均易发生主要感染,主要感染患者1年生存率更低。
要点
- 印度IIM患者主要和反复感染常见,结核需警惕。
- 每日泼尼松剂量>6.25 mg与主要感染风险相关。
- 发生主要感染的患者1年死亡率更高。
核心结论
- 印度IIM患者中主要和反复感染常见,并导致未来感染风险增加和生存率降低。
- 呼吸道感染和非典型细菌感染如结核可在疾病全程出现。
研究设计与样本
- 回顾性观察队列纳入68例IIM患者,平均年龄33.4岁,女男比4.2:1。
- 前瞻性验证队列纳入70例新诊断IIM患者,平均年龄35.7岁,女男比3.7:1。
主要发现
- 观察队列37例(54.4%)发生54次感染,其中21次(38.8%)为主要或反复感染,涉及11例(16.17%),随访3.08年。
- 观察队列结核最常见(12例,22.2%),以肺外形式为主;验证队列社区获得性肺炎最常见,其次为结核。
- 观察队列多因素分析显示,疾病初起血清蛋白(OR 0.44)、血小板(OR 0.44)和每日激素剂量(OR 1.04)预测主要感染。
- 验证队列中疾病初起血清白蛋白(OR 0.25)是唯一预测因素。
- 观察队列无感染1年生存率为73.8%,验证队列为64.7%。
关键数值与推荐
- 观察队列主要感染预测因素:血清蛋白OR 0.44,血小板OR 0.44,每日激素剂量OR 1.04。
- 验证队列主要感染预测因素:血清白蛋白OR 0.25。
- 两队列中每日泼尼松剂量>6.25 mg易发生主要感染。
- 发生主要感染的患者1年生存率为60%,无主要感染者为89.09%。
临床怎么用
- 对印度IIM患者应警惕主要和反复感染,尤其是结核和呼吸道感染。
- 每日泼尼松剂量>6.25 mg时需加强感染监测和预防。
- 发生主要感染提示预后不良,应积极干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the prevalence, profile and predictors of infections in an Indian cohort with idiopathic inflammatory myopathies (IIM). METHODS: We reviewed the records of a retrospective cohort with IIM enrolled from consecutive patients being followed up in the clinic, and these constituted the observation cohort. A newly diagnosed inception cohort with IIM were followed prospectively as the validation cohort for confirmation of observations and comparison with the observation cohort. RESULTS: Among the 68 patients in the observation cohort (average age 33.4 years, female:male 4.2:1), 37 (54.4%) experienced 54 infections between them; of these 54 infections, 21 (38.8%) were major and recurrent infections and they occurred in 11 patients (16.17%) over 3.08 years. Tuberculosis was the most common infection (12, 22.2%), with a predominance of extrapulmonary forms. Serum protein [odds ratio (OR) 0.44], platelets (0.44) at disease onset and daily steroid dose (1.04) predicted major infections on multivariate analysis. A higher daily dose of steroids at first infection correlated with number of recurrent infections. The infection-free 1-year survival was 73.8%.Of the 70 patients in the validation cohort (average age 35.7 years, female:male 3.7:1), 3 had myositis attributed to an infection. A similar proportion of the cohort experienced infections (22, 33.3%) with similar number of major (10, 45.4%) and recurrent (4, 18%) infections being recorded. The most common infection was community-acquired pneumonia, followed by tuberculosis, with serum albumin (OR 0.25) at disease onset being the only predictor. The one-year infection-free survival rate was 64.7%. Those who had a major infection had increased mortality at 1 year, with a survival rate of 60%, compared with 89.09% in those without.In both cohorts, a daily prednisone dose >6.25 mg predisposed to major infections. CONCLUSION: Major and recurrent infections are common in Indian IIM patients and confer higher risk for future infections and lower survival. Respiratory and atypical bacterial infections such as tuberculosis occur throughout the disease course.
引用
- Chatterjee R, Mehta P, Agarwal V, et al. High burden of infections in Indian patients with Idiopathic Inflammatory Myopathy: validation of observations from the MyoCite dataset. Rheumatology (Oxford). 2021. PMID: 33493341. doi:10.1093/rheumatology/keab015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。